5-YEAR OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA BY LINE OF TREATMENT FROM THE FRENCH HEMATOLOGIC MALIGNANCY REGISTRY

被引：1
|
作者：
Mounier, M. [1 ]
Gauthier, S. [1 ]
Mayandi [2 ]
Troussard, X. [3 ]
Monnereau, A. [4 ]
Guilhaume, C. [5 ]
Suzan, F. [6 ]
Blachier-Poisson, C. [5 ]
Despiegel, N. [5 ]
机构：
[1] Univ Bourgogne, Dijon, France
[2] Ctr Hosp Univ Dijon, Dijon, France
[3] CHU Caen, Caen, France
[4] Inst Bergonie, Bordeaux, France
[5] Amgen France, Paris, France
[6] Amgen Europe GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2374
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN297
引用
收藏
页码：A762 / A762
页数：1
相关论文
共 50 条
  • [41] VE-CADHERIN IN MULTIPLE MYELOMA: AN INDEPENDENT PROGNOSTIC FACTOR FOR PROGRESSION-FREE SURVIVAL
    Samura, B.
    Kolesnyk, Y.
    Syvolap, V.
    Abramov, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 796 - 797
  • [42] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    [J]. LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [43] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    [J]. Leukemia, 2011, 25 : 1620 - 1626
  • [44] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
    Moreau, Philippe
    Facon, Thierry
    Kumar, Shaji
    Plesner, Torben
    Orlowski, Robert Z.
    Bahlis, Nizar
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher
    Weisel, Katja
    Mace, Joseph R.
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Tromp, Brenda
    Delioukina, Maria
    Usmani, Saad Z.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1
  • [45] Sarcoma After 5 Years of Progression-Free Survival: Lessons From the French Sarcoma Group
    Choy, Edwin
    [J]. CANCER, 2014, 120 (19) : 2942 - 2943
  • [46] Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma
    Abudayyeh, Ala
    Lin, Heather
    Mamlouk, Omar
    Abdelrahim, Maen
    Saliba, Rima
    Rondon, Gabriela
    Martinez, Charles S.
    Delgado, Ruby
    Page, Valda
    Rajasekaran, Arun
    Sanders, Paul W.
    Qazilbash, Muzaffar
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3101 - 3111
  • [47] A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer
    Burzykowski, T
    Piccart, MJ
    Sledge, G
    Carmichael, J
    Luck, HJ
    Mackey, JR
    Nabholtz, JM
    Paridaens, R
    Biganzoli, L
    Jassem, J
    Blohmer, JU
    Bontenbal, M
    Bonneterre, J
    Chan, S
    Atalay, G
    Therasse, P
    Buyse, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S277 - S278
  • [48] CAR-T treatment: Determining the progression-free survival gain in patients with heavily pretreated multiple myeloma
    Messori, Andrea
    [J]. EJHAEM, 2020, 1 (01): : 371 - 373
  • [49] Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S334 - S335
  • [50] INCIDENCE AND SURVIVAL OF MULTIPLE MYELOMA. ANALYSIS OF A 5-YEAR PERIOD OF THE REGISTRY OF TUMORS OF THE COMMUNITY OF MADRID (RTMAD)
    Adrian, Alegre
    Gonzalo, Benzo
    Julio, Garcia-Suarez
    Jose Luis, Diez
    Joaquin, Martinez-Lopez
    Maria Jesus, Blanchard
    Beatriz, Aguado
    Cristina, Encinas
    Jose Angel, Hernandez-Rivas
    Laurentino, Benito-Parra
    Victor, Jimenez-Yuste
    Pedro, Sanchez-Godoy
    Francisco Javier, Penalver
    Alberto, Velasco
    Adriana, Pascual
    Celina, Benavente
    Pilar, Llamas
    Juan Francisco, Del Campo
    Regina, Herraez
    Gregorio, Garrido
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 139 - 139
12345